[Correspondence] Cost-effectiveness of rituximab strategies in rheumatoid arthritis

We read with interest the Article by Duncan Porter and colleagues (July 16, p 239),1 and the accompanying comment by Tom Huizinga and colleagues (July 16, p 213).2 The results of this head-to-head trial1 showed that a treatment strategy with rituximab as a first-line biological drug was not inferior to a strategy with inhibitors of tumour necrosis factor (TNF), and also suggested that this strategy was associated with substantially lower health-related costs. Even if this economic assessment could be debated, because it has been made in the context of the UK health system and is not necessarily transposable to other health systems, the study is very convincing in favour of the clinical equivalence of the two strategies and the better cost-effectiveness of rituximab.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2k7pv43
via IFTTT